

AuthentiKine [®]

Human IL-4 Sandwich ELISA Kit Datasheet

Please read it entirely before use

Catalogue Number: KE00232 Size: 96T Sensitivity: 1.4 pg/mL Range: 15.6-500 pg/mL Usage: For the quantitative detection of human IL-4 concentrations in serum, plasma and cell culture supernatant.


This product is for research use only and not for use in human or animal therapeutic or diagnostic.

Table of content	pag	e
1. Background		3
2. Principle		3
3. Required Materials		3
4. Kit Components and Storage		4
5. Safety Notes		4
6. Sample Collection and Storage		4
7. Regent Preparation		5
8. Assay Procedure Summary		6
9. Validation Data		7
9.1 Standard curve		7
9.2 Precision		8
9.3 Recovery		8
9.4 Sample values		9
9.5 Sensitivity		9
9.6 Linearity		10
10. References		10

1. Background

Interleukin-4 (IL-4), a member of the a-helical cytokine family, is produced by activated CD4 + T cells, basophils, and mast cells. It promotes the proliferation and differentiation of antigen presenting cells. IL-4 also plays a pivotal role in antibody isotype switching and stimulates the production of IgE. This cytokine has been applied in the treatment of autoimmune disorder like multiple myeloma, cancer, psoriasis, and arthritis. IL-4 has also been extensively applied to inhibit detrimental effect of Th1. It may promote the growth of epithelial tumors by mediating increased proliferation and survival.

2. Principle



Sandwich ELISA structure (Detection antibody labeled with HRP)

A capture antibody is pre-coated onto the bottom of wells which binds to analyte of interest. A detection antibody labeled with HRP also binds to the analyte. TMB acts as the HRP substrate and the solution color will change from colorless to blue. A stop solution containing sulfuric acid turns solution yellow. The color intensity is proportional to the quantity of bound protein which is measurable at 450 nm with the correction wavelength set at 630 nm.

3. Required Materials

3.1 A microplate reader capable of measuring absorbance at 450 nm with the correction wavelength set at 630 nm.

3.2 Calibrated, adjustable precision pipettes and disposable plastic tips. A manifold multi-channel pipette is recommended for large assays.

3.3 Plate washer: automated or manual.

3.4 Absorbent paper towels.

3.5 Glass or plastic tubes to prepare standard and sample dilutions.

3.6 Beakers and graduated cylinders.

3.7 Log-log or semi-log graph paper or computer and software for ELISA data analysis. A four-parameter logistic (4-PL) curve-fit is recommended.

3/10

4. Kit Components and Storage

Microplate - antibody coated 96-well microplate (8 well × 12 strips)	1 plate	Unopened Kit:
Protein standard - 1000 pg/bottle; lyophilized	2 bottles	
Detection antibody, HRP-conjugated (100×) - 120 µL/vial*	1 vial	Store at 2-8°C for 6 months or -
Additional Diluent AT-00232 - 6 mL/bottle. Only for human serum and plasma samples	1 bottle	20°C for 12 months.
Sample Diluent PT 1-ef - 30 mL/bottle		Opened Kit:
Detection Diluent - 30 mL/bottle		All reagents stored at 2-8°C for
Wash Buffer Concentrate (20×) - 30 mL/bottle	1 bottle	7 days.
Tetramethylbenzidine Substrate (TMB) - 12 mL/bottle	1 bottle	Please use a new standard
Stop Solution - 12 mL/bottle		for each assay.
Plate Cover Seals	4 pieces	ior cach assay.

* Centrifugation immediately before use

5. Safety Notes

5.1 Avoid any skin and eye contact with Stop Solution and TMB. In case of contact, wash thoroughly with water.

5.2 Do not use the kit after the expiration date.

5.3 Do not mix or substitute reagents or materials from other kit lots or other sources.

5.4 Be sure to wear protective equipment such as gloves, masks and goggles during the experiment.

5.5 When using an automated plate washer, adding a 30 second soak period following the addition of Wash Buffer to improve assay precision

6. Sample Collection and Storage

6.1 Serum: Allow blood samples to clot for 30 minutes, followed by centrifugation for 15 minutes at 1000xg. Clear serum can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.2 Plasma: Use EDTA, heparin, or citrate as an anticoagulant for plasma collection. Centrifuge for 15 minutes at 1000xg within 30 minutes of collection. The plasma can be assayed immediately or aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

6.3 Cell Culture Supernatant: Remove particulates by centrifugation for 5 minutes at 500xg and assay immediately or aliquot and store samples at \leq -20°C. Avoid repeated freeze-thaw cycles.



7. Regent Preparation

7.1 Wash Buffer (1X): If crystals have formed in the concentrate, warm to room temperature and mix gently until the crystals have completely dissolved. Add 30 mL of Wash Buffer Concentrate(20X) to 570 mL deionized or distilled water to prepare 1X Wash Buffer.


7.2 Detection Antibody, HRP-conjugated (1X): Dilute 100X Detection Antibody, HRP-conjugated 1:100 using Detection Diluent prior to assay. Suggested 1:100 dilution: 10 µL 100X Detection Antibody, HRP-conjugated + 990 µL Detection Diluent (Centrifuge the 100 X Detection Antibody solution, HRP-conjugated for a few seconds prior to use)

7.3 Sample Dilution: Different samples should be diluted with corresponding Sample Diluent, samples may require further dilution if the readout values are higher than the highest standard OD reading. Variations in sample collection, processing and storage may affect the results of the measurement.

Recommended Dilution for different sample types: 1:2 or 1:4 is recommended for human serum and plasma; undiluted or 1:2 is recommended for cell culture supernatant.

7.4 Standard Serial Dilution:

Add 2 mL Sample Diluent PT 1-ef in protein standard.



8. Assay Procedure Summary

Bring all reagents to room temperature before use (Detection antibody, HRP-conjugated can be used immediately). To avoid cross-contamination, change pipette tips between additions of each standard level, between sample additions, and between reagent additions. Also, use separate reservoirs for each reagent. 8.1 Take out the required number of microplate strips and return excess strips to the foil pouch containing the drying reagent pack and reseal; store at 4°C immediately. Microplate strips should be used in one week.

8.2 Preset the layout of the microplate, including control group, standard group and sample group;

For human serum or plasma , add 50 µL of Additional Diluent to the appropriate wells (No need incubation and wash); For cell culture supernatant , no need to add Additional Diluent, directly follow the next step.

8.3. Add 100 µL of each standard and sample to the appropriate wells.(Make sure sample addition is uninterrupted and completed within 5 to 10 minutes).

8.4 Seal plate with cover seal, pressing it firmly onto top of microwells. Incubate the plate for 60 minutes at 37°C.8.5 Wash

1) Gently remove the cover seal. Discard the liquid from wells by aspirating or decanting. Remove any residual solution by tapping the plate a few times on fresh paper towels.

Wash 4 times with 1X Wash Buffer, using at least 350-400 µL per well. Following the last wash, firmly tap plates on fresh towels 10 times to remove residual Wash Buffer. Avoid getting any towel fibers in the wells or wells drying out completely.
Add 100 µL of 1X Detection antibody, HRP-conjugated solution (refer to Reagent Preparation7.2) to each well. Seal plate with cover seal and incubate for 60 minutes at 37°C.

8.7 Repeat wash step in 8.5.

8.8 Signal development: Add 100 μL of TMB substrate solution to each well, protected from light. Incubate for 15 to 20 minutes. Substrate Solution should remain colorless until added to the plate.

8.9 Quenching color development: Add 100 μL of Stop Solution to each well in the same order as addition of the TMB substrate. Mix by tapping the side of the plate gently. NB: Avoid skin and eye contact with the Stop solution.

8.10 Read results: Immediately after adding Stop solution read the absorbance on a microplate reader at a wavelength of 450 nm. If possible, perform a double wavelength readout (450 nm and 630 nm).


8.11 Data analysis: Calculate the average of the duplicate readings (OD value) for each standard and sample, and subtract the average of the zero standard absorbance. Construct a standard curve by plotting the mean absorbance for each standard on the y-axis against the concentration on the x-axis, use four-parameter logistic curve- fit (4-PL) analysis to do this. If the samples have been diluted, the OD readout from the standard curve must be multiplied by the dilution factor used.

Step	Reagent	Volume	Incubation	Wash	Notes		
1	Additional diluent (Only for serum and plasma sample test)	50 µL	0 min	Do not wash	Add additional diluent 50 µL per well then add standard and samples immediately		
2	Standard and Samples	100 µL	60 min	4 times	Cover Wells incubate at 37°C		
3	Diluent Detection antibody, HRP- conjugated Solution	100 µL	60 min	4 times	Cover Wells incubate at 37°C		
4	TMB Substrate	100 µL	15-20 min	Do not wash	Incubate in the dark at 37°C		
5	Stop Solution	100 µL	0 min	Do not wash	-		
6	6 Read plate at 450 nm and 630 nm immediately after adding Stop solution. DO NOT exceed 5 minutes.						

9. Validation Data

9.1 Standard curve

These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.



(pg/mL)	0.D	Average	Corrected
0	0.028 0.031	0.029	-
15.6	0.073 0.078	0.076	0.046
31.25	0.127 0.14	0.134	0.104
62.5	0.289 0.287	0.288	0.259
125	0.714 0.751	0.733	0.703
250	1.658 1.648	1.653	1.624
500	2.838 2.859	2.849	2.819

9.2 Precision

Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested 20 times on one plate to assess intra-assay precision.

Inter-assay Precision (Precision between assays) Three samples of known concentration were tested in 24 separate assays to assess inter-assay precision.

Intra-assay Precision						Inter-assay Precision				
Sample	n	Mean (pg/mL)	SD	CV%		Sample	n	Mean (pg/mL)	SD	CV%
1	20	108.93	6.05	5.6		1	24	108.82	3.65	3.4
2	20	204.09	11.31	5.5		2	24	226.91	12.24	5.4
3	20	442.97	13.98	3.2		3	24	458.76	20.82	4.5

9.3 Recovery

The recovery of human IL-4 spiked to three different levels throughout the range of the assay in various matrices was evaluated.

Sample Type		Average% of Expected	Range (%)
Human placma	1:2	77	72-85
Human plasma	1:4	80	70-114
	1:2	101	88-123
Cell culture supernatant	1:4	98	83-123

9.4 Sample values

Human serum/plasma -Samples from volunteers were evaluated for human IL-4 in this assay. No medical histories were available for the donors used in this study.

Sample Type	Mean of Detectable (pg/mL)	% Detectable	Range (pg/mL)
Human serum (n=16)	18.9	31	ND*-63.3
Human plasma (n=16)	10.6	25	ND*-63

ND*=Non-detectable

Cell culture supernatant - Human peripheral blood mononuclear cells (1×10^{6} cells/mL) were cultured in RPMI-1640 supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin sulfate. The cells were unstimulated or stimulated with 10 µg/mL PHA. Aliquots of the cell culture supernatant was removed on days 1 and 5 and assayed for levels of human IL-4.

Condition	Day1 (pg/mL)	Day5 (pg/mL)
Unstimulated	-	-
Stimulated	27	-

9.5 Sensitivity

The minimum detectable dose of human IL-4 is 1.4 pg/mL. This was determined by adding two standard deviations to the concentration corresponding to the mean O.D. of 20 zero standard replicates.



9.6 Linearity

To assess the linearity of the assay, human plasma samples were spiked with high concentrations of human IL-4 in various matrices and diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay. Cell culture supernatant was diluted with the appropriate **Sample Diluent** to produce samples with values within the dynamic range of the assay.

		Human plasma	Cell culture supernatant
No Dilutend	Average% of Expected		100
	Range (%)		-
1.2	Average% of Expected	102	95
1:2	Range (%)	98-106	90-106
1:4	Average% of Expected	122	
1.4	Range (%)	116-127	
1:8	Average% of Expected	111	
1.0	Range (%)	109-114	
1:16	Average% of Expected	111	
1.10	Range (%)	110-112	

10. References

- 1. Dhanda SK. et al.(2013) Clin Dev Immunol. doi: 10.1155/2013/263952.
- 2. Müller-Hermelink N. et al. (2008) Cancer Cell.13: 507-18.
- 3. Lebman DA. et al. (1988) 168: 853-62.
- 4. provided by RefSeq, Jul 2008.

10/10